On September 17, 2020, the European Alliance for Access to Safe Medicines (EAASM) announced the availability of a report entitled Patient Safety and Nanomedicines:  The need for a centralised regulatory procedure.  According to EAASM, “[n]anomedicines and their follow-on products, also referred to as nanosimilars, are complex molecules and so regulatory oversight must be scientifically

On March 7, 2018, the Nanotechnology Industries Association (NIA) will hold a webinar on “Nanomedicine:  Diagnostics and therapeutics advancing through nanotechnology.”  The webinar will focus on the diagnostic and therapeutic applications of nanotechnology, with the agenda including:

  • Regulatory landscape in Europe and beyond for nanomaterials in healthcare applications; and
  • Industry developments within